Panion expands the cooperation for the clinical development

With an agreement and contract that connects the well-reputed biostatistician Steve Radecki (USA) to the coming clinical study in dogs with epilepsy, Panion’s professional qualifications and competences are expanded. Clinical studies used for approval of medicines must be planned and evaluated with strict statistical methodology to ensure that the results are robust and significant.

“We are very pleased with the cooperation with Steve Radecki, who has long experience in the field. This will ensure the validity of our studies and hence the usefulness in the future approval process”, says Anja Holm, CEO of Panion Animal Health AB.

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.